MarketPeel
Insider Trading Intelligence
BB

Barbara-jean Anne Bormann-kennedy

XERS
DIRECTOR · XERIS BIOPHARMA HOLDINGS, INC. · CIK 0001635065
FILING MIX · LIFETIME71%/29%
BUYS
12
SELLS
5
TOTAL VALUE
$438.3K
COMPANIES
1
ACTIVE SINCE
Jun 2020
HOLDINGS NOW
126,500
AVG SELL PX
$6.58
TRADE KIND
SHOWING 17 / 17
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
1 backtested trades · 8 horizons · 2 pending
Forward-return performance of every backtestable P/S trade by Barbara-jean Anne Bormann-kennedy, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d1+0.00%+2.37%-0.17%+2.54%+2.54%
14d1+0.00%+2.79%+1.25%+1.53%+1.53%
30d1+0.00%+9.76%+1.97%+7.80%+7.80%
60d1+0.00%+0.70%+1.52%-0.82%-0.82%
90d1+100.00%-23.57%-2.30%-21.27%-21.27%
180d1+100.00%-12.97%+8.11%-21.08%-21.08%
1y1(1 pending)
2y1(1 pending)
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
XERS · 126,500 shares · as of Jun 4, 2026
039,37578,750118,125157,500202120222023202420252026SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2020
2020
2020
2021
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
FLOW · 12 buys / 5 sellsCOVERAGE · 25 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
XERS
XERIS BIOPHARMA HOLDINGS, INC.
SALE10b5-1
10b5-1 plan
16,000$6.09$97.5K126,500Jun 4, 2026Jun 5, 2026View →
XERS
XERIS BIOPHARMA HOLDINGS, INC.
PURCHASEGRANT
Stock grant
32,996$6.15$202.9K32,996Jun 4, 2026Jun 5, 2026View →
XERS
XERIS BIOPHARMA HOLDINGS, INC.
PURCHASEGRANT
Stock grant
24,193150,693Jun 4, 2026Jun 5, 2026View →
XERS
XERIS BIOPHARMA HOLDINGS, INC.
SALE10b5-1
10b5-1 plan
15,000$7.09$106.4K142,500Dec 12, 2025Dec 15, 2025View →
XERS
XERIS BIOPHARMA HOLDINGS, INC.
PURCHASEGRANT
Stock grant
50,000157,500Jun 4, 2025Jun 4, 2025View →
XERS
XERIS BIOPHARMA HOLDINGS, INC.
PURCHASEGRANT
Stock grant
50,000107,500Jun 5, 2024Jun 5, 2024View →
XERS
XERIS BIOPHARMA HOLDINGS, INC.
PURCHASEGRANT
Stock grant
42,50057,500Jun 7, 2023Jun 7, 2023View →
XERS
XERIS BIOPHARMA HOLDINGS, INC.
PURCHASEGRANT
Stock grant
25,00025,000Jun 8, 2022Jun 9, 2022View →
XERS
XERIS BIOPHARMA HOLDINGS, INC.
PURCHASEGRANT
Stock grant
15,000$2.10$31.5K15,000Jun 8, 2022Jun 9, 2022View →
XERS
XERIS BIOPHARMA HOLDINGS, INC.
SALE
20,0000Oct 5, 2021Oct 5, 2021View →
XERS
XERIS BIOPHARMA HOLDINGS, INC.
SALE
11,2280Oct 5, 2021Oct 5, 2021View →
XERS
XERIS BIOPHARMA HOLDINGS, INC.
SALE
19,6500Oct 5, 2021Oct 5, 2021View →
XERS
XERIS BIOPHARMA HOLDINGS, INC.
PURCHASEGRANT
Stock grant
20,00020,000Oct 5, 2021Oct 5, 2021View →
XERS
XERIS BIOPHARMA HOLDINGS, INC.
PURCHASEGRANT
Stock grant
11,22811,228Oct 5, 2021Oct 5, 2021View →
XERS
XERIS BIOPHARMA HOLDINGS, INC.
PURCHASEGRANT
Stock grant
19,65019,650Oct 5, 2021Oct 5, 2021View →
XERS
XERIS BIOPHARMA HOLDINGS, INC.
PURCHASEGRANT
Stock grant
11,22811,228Jun 8, 2021Jun 8, 2021View →
XERS
XERIS BIOPHARMA HOLDINGS, INC.
PURCHASEGRANT
Stock grant
11,22811,228Jun 4, 2020Jun 4, 2020View →
Other insiders · XERS
Loading peer insiders…
About this filer
CIK 0001635065
ROLE
Director
PRIMARY
XERS
COMPANIES
1
ACTIVE SINCE
Jun 2020
MARKETPEEL · /INSIDER/0001635065DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback